Journal Title：Translational Lung Cancer Research

Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.

轉(zhuǎn)化肺癌研究（TLCR，Transl Lung Cancer Res，印刷 ISSN 2218-6751；在線 ISSN 2226-4477）是一本國際性、同行評(píng)審、開放獲取期刊，創(chuàng)刊于 2012 年 3 月。TLCR 被 PubMed/PubMed Central 和化學(xué)文摘服務(wù) (CAS) 數(shù)據(jù)庫收錄。該期刊第一年每季度出版一次，自 2013 年 2 月起每兩個(gè)月出版一次。它提供有關(guān)肺癌預(yù)防、早期檢測、診斷和治療的實(shí)用最新信息。其關(guān)注的特定領(lǐng)域包括但不限于多模態(tài)治療、標(biāo)記物、成像、腫瘤生物學(xué)、病理學(xué)、化學(xué)預(yù)防和與肺癌相關(guān)的技術(shù)進(jìn)步。

Translational Lung Cancer Research創(chuàng)刊于2012年，由Society for Translational Medicine (STM)出版商出版，收稿方向涵蓋Medicine - Oncology全領(lǐng)域，此刊是該細(xì)分領(lǐng)域中屬于非常不錯(cuò)的SCI期刊，在行業(yè)細(xì)分領(lǐng)域中學(xué)術(shù)影響力較大，專業(yè)度認(rèn)可很高，所以對(duì)原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 In-house review: 1-3 weeks; External peer review: 1-3 months; Publication Ahead of Print: within 1 month after being accepted ，影響因子指數(shù)4，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。